, Volume 43, Issue 1, pp 100–107

Assessment of endothelial function in patients with nonalcoholic fatty liver disease

  • Yasar Colak
  • Ebubekir Senates
  • Atakan Yesil
  • Yusuf Yilmaz
  • Oguzhan Ozturk
  • Levent Doganay
  • Ender Coskunpinar
  • Ozlem Timirci Kahraman
  • Banu Mesci
  • Celal Ulasoglu
  • Ilyas Tuncer
Original Article


In this study, we aimed to evaluate the endothelial functions in patients with nonalcoholic fatty liver disease (NAFLD). In this observational case–control study, a total of 51 patients with NAFLD in study group and a total of 21 with age- and sex-equivalent individuals in control group were enrolled. In both patients and control groups, levels of asymmetric dimethylarginine (ADMA), systemic endothelial function (brachial artery flow-mediated dilation) (FMD) and carotid artery intima-media thickness (C-IMT) were measured. FMD and C-IMT were evaluated by vascular ultrasound. Plasma levels of ADMA were measured by ELISA. C-IMT was significantly higher in patients with NAFLD group than control group (0.67 ± 0.09 vs. 0.52 ± 0.11 mm, P < 0.001). The average C-IMT measurements were found in groups of control, simple steatosis, and NAFLD with (borderline and definite) NASH as 0.52 ± 0.11, 0.63 ± 0.07, and 0.68 ± 0.1 mm, respectively. The differences between groups were significant (P < 0.001). Measurement of brachial artery FMD was significantly lower in patients with NAFLD group compared to control group (7.3 ± 4.8 vs. 12.5 ± 7.1 %, P < 0.001). FMD measurements in groups of control, the simple steatosis, and NAFLD with NASH as 12.5 ± 7.1, 9.64 ± 6.63, and 7.03 ± 4.57 %, respectively, and the differences were statistically significant (P < 0.001). The increase in C-IMT and decrease in FMD was independent from metabolic syndrome and it was also more evident in patients with simple steatosis and NASH compared to control group. There was no significant difference between the control and NAFLD groups in terms of plasma ADMA levels (0.61 ± 0.11 vs. 0.69 ± 0.37 μmol/L, P = 0.209). Our data suggested that NAFLD is associated with endothelial dysfunction and increased earlier in patients with atherosclerosis compared to control subjects.


Endothelial dysfunction Carotid artery intima-media thickness Brachial artery flow-mediated dilatation Asymmetric dimethylarginine 


  1. 1.
    G. Marchesini, E. Bugianesi, G. Forlani et al., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917–923 (2003)PubMedCrossRefGoogle Scholar
  2. 2.
    N. Rafiq, Z.M. Younossi, Evaluation and management of nonalcoholic fatty liver disease. Clin. Liver Dis. 13, 249–266 (2009)PubMedCrossRefGoogle Scholar
  3. 3.
    G. Perseghin, The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig. Dis. 28, 210–213 (2010)PubMedCrossRefGoogle Scholar
  4. 4.
    H. Chatrath, R. Vuppalanchi, N. Chalasani, Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver Dis. 32, 22–29 (2012)PubMedCrossRefGoogle Scholar
  5. 5.
    K. Cusi, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142, 711–725 (2012)PubMedCrossRefGoogle Scholar
  6. 6.
    R. Wang, Q. Lu, J. Feng et al., Coexistence of non-alcoholic fatty liver disease with elevated Alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine 41, 70–75 (2012)PubMedCrossRefGoogle Scholar
  7. 7.
    L.A. Adams, S. Harmsen, J.L. St Sauver et al., Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 105, 1567–1573 (2010)PubMedCrossRefGoogle Scholar
  8. 8.
    G.E. Roĭtberg, O.O. Sharkhun, T.I. Ushakova, Non-alcoholic fatty liver disease as an atherosclerosis risk factor. Eksp. Klin. Gastroenterol. 7, 20–24 (2010)PubMedGoogle Scholar
  9. 9.
    G. Targher, C.P. Day, E. Bonora, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341–1350 (2010)PubMedCrossRefGoogle Scholar
  10. 10.
    P.O. Bonetti, L.O. Lerman, A. Lerman, Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23, 168–175 (2003)PubMedCrossRefGoogle Scholar
  11. 11.
    H. Cai, D.G. Harrison, Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840–844 (2000)PubMedCrossRefGoogle Scholar
  12. 12.
    O.T. Raitakari, M. Juonala, M. Kähönen et al., Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 290, 2277–2283 (2003)PubMedCrossRefGoogle Scholar
  13. 13.
    M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall, M. Sitzer, Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115, 459–467 (2007)PubMedCrossRefGoogle Scholar
  14. 14.
    D.S. Celermajer, K.E. Sorensen, V.M. Gooch et al., Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 1111–1115 (1992)PubMedCrossRefGoogle Scholar
  15. 15.
    R. Johannides, W.K. Haefeli, L. Linder et al., Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 91, 1314–1319 (1995)CrossRefGoogle Scholar
  16. 16.
    D.S. Celermajer, M.R. Adams, P. Clarkson et al., Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 334, 150–154 (1996)PubMedCrossRefGoogle Scholar
  17. 17.
    J.A. Panza, A.A. Quyyumi, J.E. Brush Jr, S.E. Epstein, Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 323, 22–27 (1990)PubMedCrossRefGoogle Scholar
  18. 18.
    M.C. Corretti, T.J. Anderson, E.J. Benjamin et al., International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39, 257–265 (2002)PubMedCrossRefGoogle Scholar
  19. 19.
    R.H. Böger, S.M. Bode-Böger, A. Szuba et al., Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98, 1842–1847 (1998)PubMedCrossRefGoogle Scholar
  20. 20.
    J.D. Horowitz, T. Heresztyn, An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851, 42–50 (2007)PubMedCrossRefGoogle Scholar
  21. 21.
    A.J. Sanyal, AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123, 1705–1725 (2002)PubMedCrossRefGoogle Scholar
  22. 22.
    S.M. Grundy, H.B. Brewer Jr, J.I. Cleeman et al., American Heart Association and National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004)PubMedCrossRefGoogle Scholar
  23. 23.
    ACE/ADA Task Force on Inpatient Diabetes, American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Diabetes Care 29, 1955–1962 (2006)CrossRefGoogle Scholar
  24. 24.
    S.S. Moon, Y.S. Lee, S.W. Kim, Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine (2012) (Epub ahead of print)Google Scholar
  25. 25.
    D.E. Kleiner, E.M. Brunt, M. Van Natta et al., Nonalcoholic steatohepatitis clinical research network: design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005)PubMedCrossRefGoogle Scholar
  26. 26.
    J. Davignon, P. Ganz, Role of endothelial dysfunction in atherosclerosis. Circulation 109, 27–32 (2004)CrossRefGoogle Scholar
  27. 27.
    A. Sciacqua, M. Perticone, S. Miceli et al., Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr. Metab. Cardiovasc. Dis. 21, 485–491 (2011)PubMedCrossRefGoogle Scholar
  28. 28.
    O. Senturk, O. Kocaman, S. Hulagu et al., Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern. Med. J. 38, 183–189 (2008)PubMedCrossRefGoogle Scholar
  29. 29.
    G. Targher, L. Bertolini, R. Padovani et al., Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29, 1325–1330 (2006)PubMedCrossRefGoogle Scholar
  30. 30.
    E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40, 332–343 (2011)PubMedCrossRefGoogle Scholar
  31. 31.
    N. Villanova, S. Moscatiello, S. Ramilli et al., Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42, 473–478 (2005)PubMedCrossRefGoogle Scholar
  32. 32.
    T. Kasumov, J.M. Edmison, S. Dasarathy et al., Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism 60, 776–781 (2011)PubMedCrossRefGoogle Scholar
  33. 33.
    T. Dogru, H. Genc, S. Tapan et al., Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res. Clin. Pract. 96, 47–52 (2012)PubMedCrossRefGoogle Scholar
  34. 34.
    H. Yki-Jarvinen, J. Westerbacka, The fatty liver and insulin resistance. Curr. Mol. Med. 5, 287–295 (2005)PubMedCrossRefGoogle Scholar
  35. 35.
    A.J. Hanley, K. Williams, A. Festa et al., Liver markers and development of the metabolic syndrome. The ınsulin resistance atherosclerosis study. Diabetes 54, 3140–3147 (2005)PubMedCrossRefGoogle Scholar
  36. 36.
    N. Chalasani, M.A. Deeg, D.W. Crabb, Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497–1502 (2004)PubMedCrossRefGoogle Scholar
  37. 37.
    J.W. Haukeland, J.K. Damås, Z. Konopski et al., Systemic inflammation in non-alcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44, 1167–1174 (2006)PubMedCrossRefGoogle Scholar
  38. 38.
    G. Musso, R. Gambino, M. Durazzo et al., Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42, 1175–1183 (2005)PubMedCrossRefGoogle Scholar
  39. 39.
    G. Targher, L. Bertolini, S. Rodella et al., Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin. Endocrinol. 64, 679–683 (2006)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Yasar Colak
    • 1
  • Ebubekir Senates
    • 2
  • Atakan Yesil
    • 2
  • Yusuf Yilmaz
    • 3
    • 4
  • Oguzhan Ozturk
    • 1
  • Levent Doganay
    • 1
  • Ender Coskunpinar
    • 5
  • Ozlem Timirci Kahraman
    • 5
  • Banu Mesci
    • 6
  • Celal Ulasoglu
    • 1
  • Ilyas Tuncer
    • 1
  1. 1.Department of GastroenterologyIstanbul Medeniyet Universty Medical Faculty, Istanbul Goztepe Education and Research HospitalIstanbulTurkey
  2. 2.Department of GastroenterologyHaydarpasa Education and Research HospitalIstanbulTurkey
  3. 3.Department of GastroenterologyMarmara University, School of MedicineIstanbulTurkey
  4. 4.Institute of GastroenterologyMarmara UniversityIstanbulTurkey
  5. 5.Department of Molecular MedicineInstitute of Experimental Medicine (DETAE), Istanbul UniversityIstanbulTurkey
  6. 6.Department of Internal MedicineIstanbul Medeniyet University Medical Faculty, Istanbul Goztepe Education and Research HospitalIstanbulTurkey

Personalised recommendations